New MHRA Guidelines Set to Impact Medical Cannabis Product Registration and Labelling

The Medicines and Healthcare products Regulatory Agency (MHRA) is set to release comprehensive guidance across up to five different documents, covering key regulatory changes for Cannabis-Based Products for Medicinal Use (CBPM). These guidelines are designed to bring CBPMs into alignment with the standards applied to other unlicensed medications in the UK.
Registration Name Requirements:
•No References to People, Places, or Conditions: Product names cannot include references to individuals, locations, or medical conditions or symptoms (e.g., “Sleep”).
•Abbreviations: Abbreviations are allowed, but the MHRA will scrutinise their meaning. Abbreviated cultivar names may be acceptable, but further explanation may be required.
•Company Names: Only companies licensed under EU-GMP or MS standards can use their names or abbreviations in product titles.
•Character Limit: Product names must be 16 characters or fewer, including concentrations of active ingredients like THC and CBD, along with any minor cannabinoids over 1% (e.g., CBG).
•Consistency Across Documentation: The registration title must match what is shown on the product packaging, import packaging, and all associated documentation .
Packaging and Labelling:
•Plain Packaging: Packaging must be neutral, with no images, colours, or any enticing elements. It should avoid referencing people, places, or things.
•GMP-Licensed Cultivators: Only cultivators with GMP certification can be named on packaging. GACP-certified cultivators cannot be mentioned unless they also hold GMP certification .
•Terpene Information: Terpenes can be included but are subject to a variation allowance of +/- 10%.
•Patient Information via QR Codes: QR codes can be used to access Patient Information Leaflets (PILs), but the page must not link to other parts of the website.
•Certificates of Analysis (COA): COAs must be batch-specific, updated for each new batch, and included on the PIL .
Impact on Imports and Communication:
•Import Delays: All future imports must comply with these new regulations, meaning existing products will need to be re-registered, likely causing delays in availability.
•Letters of Clinical Need: Companies are prohibited from soliciting clinical need letters from doctors, who must independently determine if a product is suitable for their patients .
•Patient Communication Restrictions: Producers cannot communicate directly with patients. All discussions about treatments must be routed through clinicians or pharmacists .
We expect to see significant shifts in product names and packaging as companies work to align with the updated regulatory standards. Fortunately, the UK currently has a robust supply of medical cannabis flower available for prescription, which should cushion the impact of potential delays in restocking some medications. However, with only two part-time MHRA staff handling all unlicensed medication applications, some delays are likely unavoidable.
These changes do not reflect a change in law but rather the stricter application of existing policies and procedures. Medical cannabis is now being aligned with the same regulatory requirements as other unlicensed medicines, which will likely result in delays in the availability of new products and batches on the market.
The full impact of these changes on the industry will be assessed over the coming weeks, with further analysis to follow. Thanks you to MedBud for sharing this information on their forum here and taking the time to collate the key information.
The week in drugs and drug policy, in one email.
The newsletter opens soon. Follow the RSS feed in the meantime.

